Investigation of the effect of brexpiprazole on acute or relapse schizophrenia using the positive and negative syndrome scale: an experimental report

Article Sidebar

PDF
Published: Feb 12, 2022
DOI: https://doi.org/10.52600/2763-583X.bjcr.2022.2.1.83-89
Keywords:
Brexpiprazole, Positive and negative syndrome scale (PANSS), Schizophrenia, Antipsychotics

Main Article Content

Tetsuro Ishida
Department of Psychiatry, Hokujinkai Ishibashi Hospital & Department of Neuropsychiatry School of Medicine, Sapporo Medical University
https://orcid.org/0000-0002-8513-2373
Tomonori Murayama
Graduate school of Medicine, Sapporo Medical University & Department of Psychiatry, Kushiro Red Cross Hospital

Abstract

Brexpiprazole (BPZ) is a novel antipsychotic drug in the category of serotonin-dopamine activity modulators (SDAMs). It is expected to be effective in the treatment of schizophrenia because of its low side effects and its ability to reduce psychosis. However, clinical data in Japan are still insufficient. We prescribed BPZ to 41 schizophrenic patients; 9 of the 41 dropped out and 32 were retrospectively reviewed for psychiatric symptoms using the positive and negative syndrome scale (PANSS). The results showed that there was significant improvement in the total score, the positive scale, the negative scale and the general psychopathology scale, all after 4 weeks. The improvement started after 1 week for the total score, the positive scale and the general psychopathology scale, and after 2 weeks for the negative scale. The results suggest that BPZ is effective not only for positive symptoms in the acute phase, but also for negative symptoms after the subacute phase. Further studies are needed to investigate the efficacy of BPZ by patient's characteristics as well as by sub-items of the PANSS.

Article Details

How to Cite
Ishida, T., & Murayama, T. (2022). Investigation of the effect of brexpiprazole on acute or relapse schizophrenia using the positive and negative syndrome scale: an experimental report . Brazilian Journal of Case Reports, 2(1), 83–89. https://doi.org/10.52600/2763-583X.bjcr.2022.2.1.83-89
Issue
Vol. 2 No. 1 (2022): January/March - 2022
Section
Experimental Reports
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Author Biographies

Tetsuro Ishida, Department of Psychiatry, Hokujinkai Ishibashi Hospital & Department of Neuropsychiatry School of Medicine, Sapporo Medical University

Department of Psychiatry, Hokujinkai ISHIBASHI Hospital, Nagahashi, Otaru, Japan.

Department of Neuropsychiatry School of Medicine, Sapporo Medical University, Chuo-ku, Sapporo, Japan.

Tomonori Murayama, Graduate school of Medicine, Sapporo Medical University & Department of Psychiatry, Kushiro Red Cross Hospital

Graduate school of Medicine, Sapporo Medical University, Chuo-ku, Sapporo, Japan.

Department of Psychiatry, Kushiro Red Cross Hospital, Shinei-cho, Kushiro, Japan.

References

Otsuka Pharmaceutical Company. Otsuka and Lundbeck's Rxulti® (brexpiprazole) receives positive opinion in EU from CHMP for the treatment of schizophrenia in adults. Available in: https://www.otsuka.co.jp /en/company/newsreleases/2018/20180604_1.html

Hope J, Castle D, Keks NA. Brexpiprazole: a new leaf on the partial dopamine agonist branch. Australas Psychiatry. 2018 Feb;26(1):92-94. doi: 10.1177/1039856217732473.

Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Am J Psychiatry. 2020 Apr 1;177(4):342-353. doi: 10.1176/appi.ajp.2019.19010034.

Cohen - Mansfield J. Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument. Int Psychogeriatr. 1996;8 Suppl 3:309-15; discussion 351-4. doi: 10.1017/s1041610297003530.

Fornaro M, Fusco A, Anastasia A, Cattaneo CI, De Berardis D. Brexpiprazole for treatment-resistant major depressive disorder. Expert Opin Pharmacother. 2019 Nov;20(16):1925-1933. doi: 10.1080/ 14656566.2019.1654457.

Brown ES, Khaleghi N, Van Enkevort E, Ivleva E, Nakamura A, Holmes T, Mason BL, Escalante C. A pilot study of brexpiprazole for bipolar depression. J Affect Disord. 2019 Apr 15;249:315-318. doi: 10.1016/j.jad.2019.02. 056.

Howland RH. Brexpiprazole: another multipurpose antipsychotic drug? Journal of Psychosocial Nursing and Mental Health Services. 2015 Apr;53(4):23-5. doi: 10.3928/02793695-20150323-01.

O'Connor M. Adjunctive therapy with brexpiprazole improves treatment resistant complex post traumatic stress disorder in domestic family violence victims. Australasian Psychiatry. 2020 Jun;28(3):264-266. doi: 10.1177/ 1039856219889303.

Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019 Sep;29(9):971-985. doi: 10.1016/j.euroneuro.2019.06.008.

Watanabe Y, Yamada S, Otsubo T, Kikuchi T. Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist's Perspective. Drug Des Devel Ther. 2020 Dec 18;14:5559-5574. doi: 10.2147/ DDDT.S240859.

Antoun Reyad A, Girgis E, Mishriky R. Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2020 May;35(3):119-128. doi: 10.1097/YIC.0000000000000308.

Yoshimura Y, Shimizu H, Yamashita R, Washida K, Takeda T, Aoki S. Association between previous high-dose antipsychotic therapy and brexpiprazole discontinuation after the initiation of brexpiprazole in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol. 2020 Mar;35(2):98-104. doi: 10.1097/YIC.0000000000000296.

Inoue Y, Suzuki H, Hibino H, Takaya A, Mikami K, Yamamoto K, Matsumoto H. Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia. Brain Behav. 2021 May;11(5):e02109. doi: 10.1002/brb3.2109.